Title | Type | SJR | H index | Total Docs. (2022) | Total Docs. (3years) | Total Refs. (2022) | Total Cites (3years) | Citable Docs. (3years) | Cites / Doc. (2years) | Ref. / Doc. (2022) | %Female (2022) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
82 | Drug Topics | journal | 0.100 Q4 | 8 | 116 | 484 | 46 | 5 | 57 | 0.01 | 0.40 | 61.29 | |
81 | Pharmacy Times | trade journal | 0.100 Q4 | 8 | 0 | 444 | 0 | 2 | 299 | 0.00 | 0.00 | 0.00 | |
80 | Journal of Experimental Therapeutics and Oncology | journal | 0.107 Q4 | 40 | 0 | 17 | 0 | 2 | 16 | 0.20 | 0.00 | 0.00 | |
79 | National Toxicology Program technical report series | journal | 0.108 | 22 | 0 | 6 | 0 | 1 | 6 | 0.20 | 0.00 | 0.00 | |
78 | Food and Drug Law Journal | journal | 0.110 Q4 | 23 | 11 | 3 | 1198 | 0 | 3 | 0.00 | 108.91 | 46.67 | |
77 | Journal of Caffeine and Adenosine Research | journal | 0.111 Q4 | 1 | 0 | 8 | 0 | 3 | 5 | 0.38 | 0.00 | 0.00 | |
76 | U.S. Pharmacist | trade journal | 0.124 Q4 | 12 | 125 | 375 | 716 | 66 | 259 | 0.17 | 5.73 | 62.20 | |
75 | Adverse Drug Reaction Bulletin | journal | 0.126 Q4 | 8 | 6 | 18 | 173 | 7 | 18 | 0.42 | 28.83 | 50.00 | |
74 | NTP Immunotoxicity Technical Report Series | book series | 0.131 Q4 | 0 | 0 | 3 | 0 | 0 | 1 | 0.00 | 0.00 | 0.00 | |
73 | Pharmaceutical Chemistry Journal | journal | 0.192 Q4 | 39 | 257 | 612 | 7879 | 547 | 610 | 0.78 | 30.66 | 49.12 | |
72 | Medical Letter on Drugs and Therapeutics | journal | 0.211 Q4 | 22 | 132 | 306 | 905 | 184 | 224 | 0.71 | 6.86 | 0.00 | |
71 | Hospital Pharmacy | journal | 0.243 Q3 | 28 | 121 | 249 | 2436 | 236 | 217 | 0.84 | 20.13 | 48.11 | |
70 | Journal of Herbs, Spices and Medicinal Plants | journal | 0.255 Q3 | 34 | 27 | 93 | 938 | 143 | 93 | 1.70 | 34.74 | 36.36 | |
69 | International Journal of Medicinal Mushrooms | journal | 0.274 Q3 | 41 | 84 | 312 | 3708 | 479 | 310 | 1.37 | 44.14 | 44.92 | |
68 | Natural Product Communications | journal | 0.288 Q3 | 63 | 294 | 887 | 12870 | 1605 | 866 | 1.90 | 43.78 | 41.21 | |
67 | Clinical Neuropharmacology | journal | 0.293 Q3 | 85 | 43 | 172 | 1081 | 201 | 158 | 0.98 | 25.14 | 35.29 | |
66 | Journal of AOAC International | journal | 0.358 Q3 | 100 | 169 | 617 | 3177 | 1237 | 594 | 1.61 | 18.80 | 45.20 | |
65 | Chirality | journal | 0.382 Q3 | 83 | 119 | 303 | 6056 | 626 | 301 | 2.11 | 50.89 | 37.66 | |
64 | Critical Reviews in Therapeutic Drug Carrier Systems | journal | 0.420 Q3 | 82 | 17 | 49 | 2440 | 173 | 49 | 3.08 | 143.53 | 32.39 | |
63 | Current Cardiovascular Risk Reports | journal | 0.433 Q3 | 34 | 25 | 85 | 1868 | 101 | 85 | 1.38 | 74.72 | 57.50 | |
62 | Current Therapeutic Research | journal | 0.445 Q3 | 46 | 32 | 109 | 1105 | 220 | 103 | 1.77 | 34.53 | 41.72 | |
61 | Journal of Pharmacological and Toxicological Methods | journal | 0.445 Q3 | 83 | 47 | 190 | 1847 | 357 | 187 | 1.92 | 39.30 | 40.69 | |
60 | Journal of the American Pharmacists Association : JAPhA | journal | 0.455 Q3 | 73 | 260 | 740 | 7620 | 1230 | 605 | 1.72 | 29.31 | 63.44 | |
59 | American Journal of Health-System Pharmacy | journal | 0.464 Q3 | 107 | 398 | 1113 | 6777 | 1712 | 892 | 1.58 | 17.03 | 57.14 | |
58 | Therapeutic Drug Monitoring | journal | 0.466 Q3 | 102 | 92 | 340 | 4619 | 955 | 304 | 2.39 | 50.21 | 42.64 | |
57 | Anti-Cancer Drugs | journal | 0.471 Q3 | 102 | 239 | 427 | 7385 | 962 | 426 | 2.25 | 30.90 | 40.90 | |
56 | Journal of Ocular Pharmacology and Therapeutics | journal | 0.472 Q3 | 72 | 84 | 259 | 3831 | 566 | 233 | 2.15 | 45.61 | 40.52 | |
55 | Drug Development and Industrial Pharmacy | journal | 0.474 Q3 | 100 | 65 | 584 | 3258 | 2047 | 584 | 3.18 | 50.12 | 44.54 | |
54 | Steroids | journal | 0.477 Q3 | 114 | 110 | 397 | 5144 | 1119 | 392 | 2.85 | 46.76 | 44.29 | |
53 | Biologicals | journal | 0.479 Q3 | 66 | 34 | 195 | 1219 | 332 | 190 | 1.78 | 35.85 | 46.96 | |
52 | Reading Teacher | journal | 0.482 Q3 | 60 | 79 | 286 | 2667 | 327 | 243 | 1.10 | 33.76 | 83.85 | |
51 | Behavioural Pharmacology | journal | 0.490 Q3 | 87 | 53 | 220 | 3546 | 434 | 215 | 1.66 | 66.91 | 47.95 | |
50 | Drug and Chemical Toxicology | journal | 0.507 Q3 | 54 | 302 | 241 | 15899 | 823 | 241 | 3.23 | 52.65 | 47.42 | |
49 | American Journal of Therapeutics | journal | 0.537 Q3 | 69 | 211 | 454 | 3867 | 601 | 185 | 1.36 | 18.33 | 39.15 | |
48 | Journal of Pharmacokinetics and Pharmacodynamics | journal | 0.567 Q2 | 70 | 47 | 157 | 2117 | 387 | 147 | 2.50 | 45.04 | 33.98 | |
47 | Microbial Drug Resistance | journal | 0.589 Q2 | 78 | 134 | 581 | 5216 | 1732 | 572 | 2.77 | 38.93 | 50.64 | |
46 | Bulletin of Mathematical Biology | journal | 0.591 Q2 | 97 | 137 | 462 | 6322 | 967 | 453 | 2.20 | 46.15 | 31.95 | |
45 | Journal of Cardiovascular Pharmacology | journal | 0.641 Q2 | 109 | 210 | 498 | 9345 | 1403 | 464 | 2.67 | 44.50 | 41.26 | |
44 | Contemporary Clinical Trials Communications | journal | 0.642 Q2 | 26 | 156 | 530 | 6877 | 915 | 523 | 1.53 | 44.08 | 53.45 | |
43 | Pharmaceutical Research | journal | 0.644 Q2 | 229 | 234 | 581 | 13222 | 2258 | 568 | 3.53 | 56.50 | 34.87 | |
42 | Cancer Biotherapy and Radiopharmaceuticals | journal | 0.650 Q2 | 68 | 108 | 260 | 4014 | 897 | 255 | 3.81 | 37.17 | 37.69 | |
41 | Neuropsychopharmacology Reports | journal | 0.651 Q2 | 22 | 76 | 165 | 2193 | 449 | 163 | 2.74 | 28.86 | 25.60 | |
40 | Profiles of Drug Substances, Excipients and Related Methodology | journal | 0.663 Q2 | 29 | 7 | 24 | 608 | 185 | 7 | 7.64 | 86.86 | 0.00 | |
39 | Basic and Clinical Pharmacology and Toxicology | journal | 0.681 Q2 | 103 | 125 | 422 | 5327 | 1286 | 402 | 2.77 | 42.62 | 42.67 | |
38 | Journal of Clinical Pharmacology | journal | 0.691 Q2 | 130 | 178 | 564 | 7307 | 1587 | 522 | 2.74 | 41.05 | 42.60 | |
37 | Experimental and Clinical Psychopharmacology | journal | 0.718 Q2 | 101 | 104 | 276 | 5904 | 736 | 274 | 2.15 | 56.77 | 54.82 | |
36 | Journal of Biopharmaceutical Statistics | journal | 0.721 Q2 | 56 | 66 | 222 | 1892 | 235 | 208 | 0.93 | 28.67 | 40.00 | |
35 | Prostaglandins and Other Lipid Mediators | journal | 0.733 Q2 | 86 | 42 | 162 | 2362 | 546 | 157 | 3.16 | 56.24 | 46.64 | |
34 | Topics in antiviral medicine | journal | 0.778 Q2 | 46 | 13 | 45 | 330 | 110 | 42 | 0.87 | 25.38 | 38.24 | |
33 | Human gene therapy methods | journal | 0.780 Q2 | 38 | 0 | 24 | 0 | 87 | 24 | 0.00 | 0.00 | 0.00 |
Follow us on @ScimagoJR
Scimago Lab, Copyright 2007-2024. Data Source: Scopus®